Glaxosmi. Pharma

37
Sell
  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE159A01016
  • NSEID: GLAXO
  • BSEID: 500660
INR
2,546.00
36.7 (1.46%)
BSENSE

Dec 05

BSE+NSE Vol: 1.62 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
No of Months
12
12
12
12
12
12
Operating Income
3,453.00
3,251.00
3,278.00
2,925.00
3,224.00
3,128.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
3,453.00
3,251.00
3,278.00
2,925.00
3,224.00
3,128.00
Expenditure (Ex Depriciation)
Stock Adjustments
-63.00
68.00
15.00
-38.00
-35.00
25.00
Raw Materials Consumed
1,398.00
1,215.00
1,340.00
1,294.00
1,343.00
1,332.00
Power & Fuel Cost
29.00
29.00
27.00
26.00
33.00
27.00
Employee Cost
624.00
594.00
610.00
616.00
628.00
537.00
Operating Expenses
113.00
99.00
120.00
110.00
110.00
115.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
163.00
161.00
178.00
104.00
162.00
183.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
68.00
68.00
58.00
75.00
113.00
107.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
2,545.00
2,447.00
2,516.00
2,327.00
2,567.00
2,527.00
Operating Profit (PBDIT) excl Other Income
908.00
804.00
761.00
598.00
657.00
600.00
Other Income
122.00
100.00
75.00
110.00
79.00
102.00
Operating Profit (PBDIT)
1,031.00
904.00
837.00
708.00
736.00
703.00
Interest
1.00
1.00
1.00
3.00
6.00
0.00
Profit before Depriciation and Tax
1,029.00
903.00
835.00
705.00
729.00
702.00
Depreciation
69.00
65.00
68.00
78.00
82.00
48.00
Profit Before Taxation & Exceptional Items
959.00
837.00
767.00
626.00
647.00
653.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
816.00
836.00
779.00
453.00
305.00
682.00
Provision for Tax
226.00
228.00
398.00
166.00
212.00
237.00
Profit After Tax
589.00
607.00
380.00
287.00
93.00
445.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
828.00
1,742.00
556.00
875.00
1,190.00
1,102.00
Profit Available for appropriations
1,418.00
2,350.00
936.00
1,162.00
1,283.00
1,548.00
Appropriations
1,418.00
2,350.00
936.00
1,162.00
1,283.00
1,548.00
Equity Dividend (%)
320.00%
320.00%
900.00%
300.00%
400.00%
200.00%
Earnings Per Share
34.83
36.05
100.04
21.14
5.50
26.29
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 9.28% vs 5.94% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 29.83% vs 12.66% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is -26.94% vs -0.67% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 57.19% vs -3.31% in Mar 2024

Compare Profit and Loss Results of Glaxosmi. Pharma
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
3,453.00
15,261.00
-11,808.00
-77.37%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
3,453.00
15,261.00
-11,808.00
-77.37%
Expenditure (Ex Depriciation)
Stock Adjustments
-63.00
294.00
-357.00
-121.43%
Raw Materials Consumed
1,398.00
4,903.00
-3,505.00
-71.49%
Power & Fuel Cost
29.00
377.00
-348.00
-92.31%
Employee Cost
624.00
3,144.00
-2,520.00
-80.15%
Operating Expenses
113.00
1,005.00
-892.00
-88.76%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
163.00
649.00
-486.00
-74.88%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
68.00
175.00
-107.00
-61.14%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
2,545.00
12,095.00
-9,550.00
-78.96%
Operating Profit (PBDIT) excl Other Income
908.00
3,166.00
-2,258.00
-71.32%
Other Income
122.00
1,208.00
-1,086.00
-89.90%
Operating Profit (PBDIT)
1,031.00
4,374.00
-3,343.00
-76.43%
Interest
1.00
897.00
-896.00
-99.89%
Profit before Depriciation and Tax
1,029.00
3,477.00
-2,448.00
-70.41%
Depreciation
69.00
1,687.00
-1,618.00
-95.91%
Profit Before Taxation & Exceptional Items
959.00
1,790.00
-831.00
-46.42%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
816.00
1,886.00
-1,070.00
-56.73%
Provision for Tax
226.00
457.00
-231.00
-50.55%
Profit After Tax
589.00
1,429.00
-840.00
-58.78%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
828.00
17,602.00
-16,774.00
-95.30%
Profit Available for appropriations
1,418.00
18,616.00
-17,198.00
-92.38%
Appropriations
1,418.00
18,616.00
-17,198.00
-92.38%
Equity Dividend (%)
320%
10%
310.00
Earnings Per Share
34.83
8.46
26.37
311.70%
Profit And Loss - Net Sales
Net Sales 3,723.49 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 9.28% vs 5.94% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 1,169.29 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 29.83% vs 12.66% in Mar 2024

Profit And Loss - Interest
Interest 1.31 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -26.94% vs -0.67% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 919.05 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 57.19% vs -3.31% in Mar 2024